Search

Your search keyword '"Beauchant M"' showing total 235 results
Start Over Author "Beauchant M"
235 results on '"Beauchant M"'

1. Liver fibrosis staging with contrast-enhanced ultrasonography: prospective multicenter study compared with METAVIR scoring

Author

Staub, F., Tournoux-Facon, C., Roumy, J., Chaigneau, C., Morichaut-Beauchant, M., Levillain, P., Prevost, C., Aubé, C., Lebigot, J., Oberti, F., Galtier, J. B., Laumonier, H., Trillaud, H., Bernard, P. H., Blanc, J. F., Sironneau, S., Machet, F., Drouillard, J., de Ledinghen, V., Couzigou, P., Foucher, P., Castéra, L., Tranquard, F., Bacq, Y., d’Altéroche, L., Ingrand, P., and Tasu, J. P.

Published
2009
Full Text
View/download PDF

13. Clinical trial: short-term effects of combination of satavaptan, a selective vasopressin V2receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatremia - a randomized, double-blind, placebo-controlled study

Author

Ginès P, Wong F, Watson H, Terg R, Bruha R, Zarski JP, Dudley F, NormoCAT study investigators: Angeli P, Angus P, Bilic A, Bronowicki JP, Chira C, Dobru D, Doffoel M, Fleig W, Fraticiu A, Gadano A, Gerbes A, Gheorge L, Goldis A, Grigorescu M, Horsmans Y, Hulek P, Lata J, Lonovics J, Manns M, Masliah C, Morichaut Beauchant M, Olteanu D, Pascu O, Planas R, Ramdani M, Ruiz del Arbol L, Siahmed SN, Stoica V, Ujszaszy L, Voiosu M.R., BERNARDI, MAURO, Ginès P, Wong F, Watson H, Terg R, Bruha R, Zarski JP, Dudley F, NormoCAT study investigators: Angeli P, Angus P, Bernardi M, Bilic A, Bronowicki JP, Chira C, Dobru D, Doffoel M, Fleig W, Fraticiu A, Gadano A, Gerbes A, Gheorge L, Goldis A, Grigorescu M, Horsmans Y, Hulek P, Lata J, Lonovics J, Manns M, Masliah C, Morichaut-Beauchant M, Olteanu D, Pascu O, Planas R, Ramdani M, Ruiz del Arbol L, Siahmed SN, Stoica V, Ujszaszy L, and Voiosu MR.

Subjects
Liver Cirrhosis, Male, medicine.medical_specialty, Cirrhosis, Morpholines, VASOPRESSIN V2 RECEPTORS, medicine.medical_treatment, Placebo-controlled study, Spironolactone, Placebo, Gastroenterology, chemistry.chemical_compound, Double-Blind Method, Furosemide, Internal medicine, Ascites, Humans, Medicine, Spiro Compounds, Pharmacology (medical), Prospective Studies, Diuretics, CIRRHOSIS, SATAVAPTAN, Aged, HYPONATREMIA, Hepatology, business.industry, Body Weight, Middle Aged, medicine.disease, Surgery, Drug Combinations, Satavaptan, Treatment Outcome, chemistry, Female, ASCITES, Diuretic, medicine.symptom, business, Hyponatremia, Antidiuretic Hormone Receptor Antagonists
Abstract

Aliment Pharmacol Ther 31, 834–845 Summary Background There is little information on the effects of vaptans in patients with cirrhosis. Aim To investigate the short-term effects of satavaptan, a selective vasopressin V2 receptor antagonist on ascites in cirrhosis without hyponatraemia. Methods A total of 148 patients with cirrhosis, ascites and serum sodium >130 mmol/L were included in a multicentre, double-blind, randomized, controlled study of 14 days comparing three fixed doses of satavaptan (5 mg, 12.5 mg or 25 mg once daily) vs. placebo. Average MELD scores were: 13.4, 12.3, 13.8 and 13.1 respectively. All patients received spironolactone 100 mg/day plus furosemide 20–25 mg/day. Results Satavaptan treatment was associated with a decrease in ascites (mean change in body weight was −0.36 kg (±3.03) for placebo vs. −2.46 kg (±3.11), −2.08 kg (±4.17) and −2.28 kg (±3.24) for the 5 mg, 12.5 mg and 25 mg doses respectively; P = 0.036, P = 0.041 and P = 0.036 for satavaptan 5, 12.5 and 25 mg/day vs. placebo respectively). Thirst and slight increases in serum sodium were more common in patients treated with satavaptan compared with placebo, while other adverse events were similar. Conclusions The administration satavaptan for a 14-day period is associated with reduction in ascites in patients with moderately severe cirrhosis without hyponatraemia under diuretic treatment.

Published
2010

17. [Effects of smoking on the thyroid gland, digestive system, kidney and bone]

Author

Underner, M., Hadjadj, S., Beauchant, M., Bridoux, Franck, Debiais, F., Meurice, J.-C., Carrion, Claire, Physiologie Moléculaire de la Réponse Immune et des Lymphoproliférations (PMRIL), and Université de Limoges (UNILIM)-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)-Centre National de la Recherche Scientifique (CNRS)

Subjects
MESH: Kidney Diseases, MESH: Smoking, MESH: Humans, [SDV.IMM] Life Sciences [q-bio]/Immunology, Digestive System Diseases, Smoking, Thyroid Diseases, MESH: Digestive System Diseases, Risk Factors, MESH: Risk Factors, Humans, MESH: Thyroid Diseases, [SDV.IMM]Life Sciences [q-bio]/Immunology, Kidney Diseases, MESH: Bone Diseases, Bone Diseases
Abstract

International audience; INTRODUCTION: In addition to being a major cardiovascular risk factor, smoking promotes or worsens thyroid, digestive, renal and bone diseases. BACKGROUND: Smoking is positively associated with hyperthyroidism. It is associated with Graves' disease and it especially increases the risk of the development of severe exophthalmos. In contrast, smoking might exert a protective action for thyroid carcinoma. Smoking increases the severity of hepatic lesions in patients with chronic hepatitis C. Smoking accelerates the progression of primary biliary cirrhosis and increases the risk of hepatocellular carcinoma. Smoking increases risk of both hyperplastic and adenomatous polyps. While Crohn's disease is associated with smoking, ulcerative colitis is largely a disease of non smokers. Smoking increases risk of development of both renal cell carcinoma and chronic nephropathies, particularly in types 1 and 2 diabetes. Smoking is a risk factor for decreased bone density and is associated with a significantly increased risk of fracture. Smoking is related to the development of rheumatoid arthritis and may adversely influence its severity. CONCLUSIONS: Smoking might be considered a risk factor for the development of several thyroid, digestive, renal and bone diseases. Consequently, smoking prevention and cessation programs must be strongly encouraged among the patients concerned.

Published
2008

20. Early biliary stent obstruction : physiopathologic study in a porcine model

Author

Maillot, N., Bon, D., Dugue, T., Robert, S., Moesch, C., Aucher, P., Caritez, J.C., Beauchant, M., Carretier, Michel, Génétique Expérimentale en Productions Animales (GEPA), Institut National de la Recherche Agronomique (INRA), and ProdInra, Migration

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
1996

21. Elimination of epinephride during CVVH : experimental model in piglets

Author

Rouffineau, J., Robert, S., CARITEZ, J.C., Fournier, F., Robert, R., Lecron, J.C., CARRETIER, MICHEL, Beauchant, M., Génétique Expérimentale en Productions Animales (GEPA), Institut National de la Recherche Agronomique (INRA), and ProdInra, Migration

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

National audience

Published
1995

22. Obstruction précoce des endoprothèses biliaires : étude physiopathologique chez le porc

Author

Maillot, N., Moesch, C., Aucher, P., Bon, D., Caritez, J.C., Carretier, Michel, Beauchant, M., ProdInra, Migration, Génétique Expérimentale en Productions Animales (GEPA), and Institut National de la Recherche Agronomique (INRA)

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

National audience

Published
1995

23. Dépistage du carcinome épidermoïde de l'œsophage par chromoendoscopie au lugol chez des patients avec carcinome épidermoïde ORL: expérience monocentrique chez 424 patients

Author

Stroeymeyt, K, primary, Wangermez, M, additional, Michaud-Herbst, A, additional, Allières, C, additional, Tougeron, D, additional, Thomas, D, additional, Charier, F, additional, Dufour, X, additional, Beau, P, additional, Chagneau Derrode, C, additional, Beauchant, M, additional, Silvain, C, additional, and Barrioz, T, additional

Published
2011
Full Text
View/download PDF

35. P.370 Intérêt de l’échographie de contraste pour le diagnostic de fibrose hépatique : comparaison avec l’histologie

Author

Prévost, C., primary, Tournoux Facon, C., additional, Chagneau, C., additional, Staub, F., additional, Oberti, F., additional, Aube, C., additional, Bernard, P.H., additional, Trillaud, H., additional, de Ledinghen, V., additional, Drouillard, J., additional, d’Alteroche, L., additional, Tranquart, F., additional, Roumy, J., additional, Levillain, P., additional, Ingrand, P., additional, Morichaud-Beauchant, M., additional, and Tasu, J.P., additional

Published
2009
Full Text
View/download PDF

39. Intravenous nitroglycerin for prevention of pancreatitis after therapeutic endoscopic retrograde cholangiography: a randomized, double-blind, placebo-controlled multicenter trial

Author

Beauchant, M., primary, Ingrand, P., additional, Favriel, J., additional, Dupuychaffray, J., additional, Capony, P., additional, Moindrot, H., additional, Barthet, M., additional, Escourrou, J., additional, Plane, C., additional, Barrioz, T., additional, Lacoste, L., additional, and Ingrand, I., additional

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results